TMR Research

The treatment of IMDs is broadly classified into dietary restrictions, dietary supplementation, drugs that inhibit or regulate metabolism, transplantation of the concerned organ, gene therapy, and dialysis in severe cases.

Globally, IMD affects nearly one in every 2,500 to 5,000 individuals with nearly 300 to 600 new cases found in the U.K., according to Public Health Genetics U.K. The specificity and high risk affinity of IMD varies from disorder to disorder, with some disorders like familial cylomicronemia being closely associated with Caucasians and others like porphyria being recoded largely among African Americans. These metabolic disorders are often controllable with certain lifestyle and diet changes, including Familial Cylomicronemia and Phenylketonuria. But some IMDs are highly dangerous and may affect the survivability of a person, such as Huntington's or Zellweger syndrome.

A lot of IMDs arise when the mutated gene responsible is inherited by the natural selection process and a large number of these genes are recessive. This is probably why a large number of these metabolic disorders are rare occurrences, whereas certain other genes are dominant in nature; this makes it difficult for a willing parent to conceive a child as the risk for transferring a gene remains high (e.g. Huntington's). Familial chylomicronemia occurs when an individual genetically inherits Lipoprotein lipase enzyme mutation. This is a very rare genetic disease at occurrence rate of 1 individual per million with chances of symptoms occurring only in homozygous individuals (receiving mutation genes from both parents) or in other words recessive gene transmission.

Nowadays, genetic screening via mass spectrometry and DNA testing of all newborn children are done in nearly all of the developed countries and also some developing countries of the world, including India, China, and Brazil, albeit across a small percentage of the national population. This prepares a parent and the child with the necessary precautions and treatment for increasing the longevity of the concerned newborn. The life expectancy of such a child with all the necessary care and precaution is at par with the average individual.

However among many adult populations and in some children, rare genetic metabolic disorders are abruptly presented and often not accurately diagnosed. In such individuals, abnormal metabolic changes are considered to be a type of genetic mutation in routine diagnosis. Symptoms such as growth failure, precocious puberty and development delay in children below 12, and anemia, neurological disorder, cancer, muscle weakness, rapid hormonal changes, and skin changes in adults, are regarded to probably have a genetic metabolic cause.

The treatment of IMDs is broadly classified into dietary restrictions, dietary supplementation, drugs that inhibit or regulate metabolism, transplantation of the concerned organ, gene therapy, and dialysis in severe cases. In the case of familial cylomicronemia, gene therapy includes Alipogene tiparvovec recombinant gene therapy drug, manufactured by UniQure Inc. This therapy utilizes viruses (adenovirus vector) designed in such a way that upon infection, the gene for producing the lipoprotein lipase is induced into the host cell, thereby producing the enzyme in-vivo. This therapy has shown positive results and is expected to be released into the market soon. For now, the global IMD treatment market lies broadly in the dietary supplements market.

Global Inherited Metabolic Disorders Market: Regional Evaluation

The overall estimated global populations of IMD individuals lie in few millions. The niche category of this segment gives little market for specific condition-related products. However, the implications of therapy are huge as some treatments have the potential to completely eradicate these disorders. Several suitable models have been considered for the treatment of hypercholesterolemia and dyslipidemia, which can in turn alter the outcome of cardiovascular diseases to a bare minimum in the future. For now, the market is open for limitless possibilities.

The market lays primarily with the Caucasian and African American populations of world, especially in North America, Europe, Australia, and Africa, followed by the minority populations from South Asia and East Asia.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today's supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients' conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.